Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) FCF Margin (2020 - 2025)

Historic FCF Margin for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to 57.8%.

  • Tango Therapeutics' FCF Margin rose 2308600.0% to 57.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 220.7%, marking a year-over-year increase of 632300.0%. This contributed to the annual value of 314.38% for FY2024, which is 128000.0% up from last year.
  • Tango Therapeutics' FCF Margin amounted to 57.8% in Q3 2025, which was up 2308600.0% from 1167.65% recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' FCF Margin ranged from a high of 44.1% in Q2 2021 and a low of 1167.65% during Q2 2025
  • For the 5-year period, Tango Therapeutics' FCF Margin averaged around 435.69%, with its median value being 330.78% (2022).
  • As far as peak fluctuations go, Tango Therapeutics' FCF Margin soared by 4056800bps in 2023, and later tumbled by -10472600bps in 2025.
  • Over the past 5 years, Tango Therapeutics' FCF Margin (Quarter) stood at 307.87% in 2021, then tumbled by -48bps to 457.14% in 2022, then decreased by -12bps to 509.91% in 2023, then crashed by -75bps to 893.15% in 2024, then skyrocketed by 94bps to 57.8% in 2025.
  • Its FCF Margin was 57.8% in Q3 2025, compared to 1167.65% in Q2 2025 and 774.26% in Q1 2025.